{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:52:58Z","timestamp":1790394778719,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,7,4]],"date-time":"2010-07-04T00:00:00Z","timestamp":1278201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s11060-010-0279-5","type":"journal-article","created":{"date-parts":[[2010,7,3]],"date-time":"2010-07-03T18:17:44Z","timestamp":1278181064000},"page":"345-355","source":"Crossref","is-referenced-by-count":7,"title":["High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma"],"prefix":"10.1007","volume":"101","author":[{"given":"Christopher J.","family":"Campen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Tombleson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myke R.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,7,4]]},"reference":[{"key":"279_CR1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1023\/A:1006290032052","volume":"43","author":"M Schabet","year":"1999","unstructured":"Schabet M (1999) Epidemiology of primary CNS lymphoma. J Neuro-Oncol 43:199\u2013201","journal-title":"J Neuro-Oncol"},{"key":"279_CR2","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","volume":"20","author":"LM DeAngelis","year":"2002","unstructured":"DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93\u201310. J Clin Oncol 20:4643\u20134648","journal-title":"J Clin Oncol"},{"key":"279_CR3","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","volume":"374","author":"AJM Ferreri","year":"2009","unstructured":"Ferreri AJM, Reni M, Foppoli M et al (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512\u20131520","journal-title":"Lancet"},{"key":"279_CR4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1470-2045(00)00390-9","volume":"2","author":"SR Plotkin","year":"2001","unstructured":"Plotkin SR, Batchelor TT (2001) Primary nervous-system lymphoma. Lancet Oncol 2:354\u2013365","journal-title":"Lancet Oncol"},{"key":"279_CR5","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.5858\/132.11.1830","volume":"132","author":"S Bhagavathi","year":"2008","unstructured":"Bhagavathi S, Wilson J (2008) Primary central nervous system lymphoma. Arch Pathol Lab Med 132:1830\u20131834","journal-title":"Arch Pathol Lab Med"},{"key":"279_CR6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","volume":"21","author":"AJM Ferrari","year":"2003","unstructured":"Ferrari AJM, Blay JY, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J Clin Oncol 21:266\u2013272","journal-title":"J Clin Oncol"},{"key":"279_CR7","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","volume":"24","author":"L Abrey","year":"2006","unstructured":"Abrey L, Ben-Porat L, Panageas KS et al (2006) Primary central nervous system lymphoma: the memorial sloan-kettering cancer center prognostic model. J Clin Oncol 24:5711\u20135715","journal-title":"J Clin Oncol"},{"key":"279_CR8","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","volume":"24","author":"IT Gavrilovic","year":"2006","unstructured":"Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570\u20134574","journal-title":"J Clin Oncol"},{"key":"279_CR9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/14737175.6.5.635","volume":"6","author":"MR Green","year":"2006","unstructured":"Green MR, Chowdhary S, Lombardi KM, Chalmers LM, Chamberlain M (2006) Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma. Expert Rev Neurother 6:635\u2013652","journal-title":"Expert Rev Neurother"},{"key":"279_CR10","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1200\/JCO.2005.01.161","volume":"23","author":"PL Nguyen","year":"2005","unstructured":"Nguyen PL, Chakravarti A, Finkelstein DM et al (2005) Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 23:1507\u20131513","journal-title":"J Clin Oncol"},{"key":"279_CR11","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1158\/1078-0432.CCR-04-0159","volume":"10","author":"SR Plotkin","year":"2004","unstructured":"Plotkin SR, Betensky RA, Hochberg FH et al (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 10:5643\u20135646","journal-title":"Clin Cancer Res"},{"key":"279_CR12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/jnci\/92.7.575","volume":"92","author":"M Reni","year":"2000","unstructured":"Reni M, Ferreri AJM, Landoni C, Villa E (2000) Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 92:575\u2013576","journal-title":"J Natl Cancer Inst"},{"key":"279_CR13","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.ejca.2004.03.008","volume":"40","author":"M Reni","year":"2004","unstructured":"Reni M, Mason W, Zaja F et al (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40:1682\u20131688","journal-title":"Eur J Cancer"},{"key":"279_CR14","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.bjc.6603660","volume":"96","author":"M Reni","year":"2007","unstructured":"Reni M, Zaja F, Mason W et al (2007) Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 96:864\u2013867","journal-title":"Br J Cancer"},{"key":"279_CR15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1212\/01.WNL.0000137050.43114.42","volume":"63","author":"RH Enting","year":"2004","unstructured":"Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63:901\u2013903","journal-title":"Neurology"},{"key":"279_CR16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cncr.20339","volume":"101","author":"ET Wong","year":"2004","unstructured":"Wong ET, Tishler R, Barron L, Wu J (2004) Immunochemotherapy with rituximab and temozolomide for PCNSL. Cancer 101:139\u2013145","journal-title":"Cancer"},{"key":"279_CR17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11060-006-9324-9","volume":"83","author":"V Pitini","year":"2007","unstructured":"Pitini V, Baldari S, Altavilla G, Arrigo C, Naro C, Perniciaro F (2007) Salvage therapy for primary central nervous system lymphoma with 90Y-ibritumomab and temozolomide. J Neurooncol 83:291\u2013293","journal-title":"J Neurooncol"},{"key":"279_CR18","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1212\/01.WNL.0000125334.16420.D4","volume":"62","author":"L Fischer","year":"2004","unstructured":"Fischer L, Thiel E, Klasen HA, Kirchen H, Jahnke K, Korfel A (2004) Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 62:1885\u20131887","journal-title":"Neurology"},{"key":"279_CR19","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mdl070","volume":"17","author":"L Fischer","year":"2006","unstructured":"Fischer L, Thiel E, Klasen HA et al (2006) Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 17:1141\u20131145","journal-title":"Ann Oncol"},{"key":"279_CR20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-007-9464-6","volume":"86","author":"AD Voloschin","year":"2008","unstructured":"Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T (2008) Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neuro-Oncol 86:211\u2013215","journal-title":"J Neuro-Oncol"},{"key":"279_CR21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1034\/j.1600-0609.2003.00045.x","volume":"70","author":"E Arellano-Ridrigo","year":"2003","unstructured":"Arellano-Ridrigo E, L\u00f3pez-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F (2003) Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 70:219\u2013224","journal-title":"Eur J Haematol"},{"key":"279_CR22","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1080\/10428190701370605","volume":"48","author":"R Yamanaka","year":"2007","unstructured":"Yamanaka R, Homma J, Sano M et al (2007) Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study. Leuk Lymphoma 48:1429\u20131433","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"279_CR23","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1212\/WNL.54.8.1707","volume":"54","author":"U Herrlinger","year":"2000","unstructured":"Herrlinger U, Brugger W, Bamberg M, K\u00fcker W, Dichgans J, Weller M (2000) PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 54(8):1707\u20131708","journal-title":"Neurology"},{"key":"279_CR24","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1592\/phco.24.14.1347.43154","volume":"24","author":"B Goldspiel","year":"2004","unstructured":"Goldspiel B (2004) Chemotherapy dose density in early-stage breast cancer and non-Hodgkin\u2019s lymphoma. Pharmacotherapy 24:1347\u20131357","journal-title":"Pharmacotherapy"},{"key":"279_CR25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.1990.8.6.963","volume":"8","author":"LW Kwak","year":"1990","unstructured":"Kwak LW, Halpern J, Olshen RA, Horning SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree structured survival analysis. J Clin Oncol 8:963\u2013977","journal-title":"J Clin Oncol"},{"key":"279_CR26","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/1097-0142(19900915)66:6<1124::AID-CNCR2820660608>3.0.CO;2-T","volume":"66","author":"R Epelbaum","year":"1990","unstructured":"Epelbaum R, Faraggi D, Ben-Arie Y et al (1990) Survival of diffuse large cell lymphoma. A multi-variate analysis including dose intensity variables. Cancer 66:1124\u20131129","journal-title":"Cancer"},{"key":"279_CR27","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2003-02-0542","volume":"102","author":"H Tilly","year":"2003","unstructured":"Tilly H, Lepage E, Coiffier B et al (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284\u20134289","journal-title":"Blood"},{"key":"279_CR28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626\u2013633","journal-title":"Blood"},{"key":"279_CR29","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634\u2013641","journal-title":"Blood"},{"key":"279_CR30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.exphem.2006.04.014","volume":"34","author":"LA Holmberg","year":"2006","unstructured":"Holmberg LA, Stewart FM (2006) Revisiting the role of dose intensity in hematological malignancies. Exp Hematol 34:811\u2013825","journal-title":"Exp Hematol"},{"key":"279_CR31","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med 333:1540\u20131545","journal-title":"N Engl J Med"},{"key":"279_CR32","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa031770","volume":"350","author":"N Milpied","year":"2004","unstructured":"Milpied N, Deconinck E, Gaillard F et al (2004) Groupe Ouest-Est des Leuc\u00e9mies et des Autres Maladies du Sang. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287\u20131295","journal-title":"N Engl J Med"},{"key":"279_CR33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1023760824739","volume":"63","author":"T Watanabe","year":"2003","unstructured":"Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama T, Fukushima T (2003) Long term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy. J Neuro-Oncol 63:87\u201395","journal-title":"J Neuro-Oncol"},{"key":"279_CR34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/annonc\/mdn628","volume":"20","author":"G Illerhaus","year":"2009","unstructured":"Illerhaus G, Marks R, M\u00fcller F et al (2009) High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 20:319\u2013325","journal-title":"Ann Oncol"},{"key":"279_CR35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.bjc.6605559","volume":"102","author":"M Joerger","year":"2010","unstructured":"Joerger M, Huitema ADR, Kr\u00e4henb\u00fchl S et al (2010) Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 102:673\u2013677","journal-title":"Br J Cancer"},{"key":"279_CR36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bjc.6601472","volume":"90","author":"AJ Ferreri","year":"2004","unstructured":"Ferreri AJ, Guerra E, Regazzi M et al (2004) Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 90:353\u2013358","journal-title":"Br J Cancer"},{"key":"279_CR37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1146\/annurev.pharmtox.47.120505.105237","volume":"47","author":"AG Boer de","year":"2007","unstructured":"de Boer AG, Gaillard PJ (2007) Drug targeting to the brain. Ann Rev Pharmacol Toxicol 47:325\u2013355","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"279_CR38","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.2006.09.9861","volume":"25","author":"LL Muldoon","year":"2007","unstructured":"Muldoon LL, Soussain C, Jahnke K et al (2007) Chemotherapy delivery issues in central nervous system malignancies: a reality check. J Clin Oncol 25:2295\u20132305","journal-title":"J Clin Oncol"},{"key":"279_CR39","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1212\/01.WNL.0000156350.49336.E2","volume":"64","author":"K Fliessbach","year":"2005","unstructured":"Fliessbach K, Helmstaedter C, Urbach H et al (2005) Neuropsychological outcome after chemotherapy for primary CNS lymphoma. Neurology 64:1184\u20131188","journal-title":"Neurology"},{"key":"279_CR40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1023\/A:1006298201101","volume":"43","author":"U Herrlinger","year":"1999","unstructured":"Herrlinger U, Schabet M, Bitzer D, Petersen D, Krauseneck P (1999) Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol 43:219\u2013226","journal-title":"J Neurooncol"},{"key":"279_CR41","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1200\/JCO.1994.12.3.627","volume":"12","author":"JR Crossen","year":"1994","unstructured":"Crossen JR, Garwood D, Glatstein E, Neuwelt EA (1994) Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12:627\u2013642","journal-title":"J Clin Oncol"},{"key":"279_CR42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/WNL.59.1.40","volume":"59","author":"CL Armstrong","year":"2002","unstructured":"Armstrong CL, Hunter JV, Ledakis GE et al (2002) Late cognitive and radiographic changes related to radiotherapy. Neurology 59:40\u201348","journal-title":"Neurology"},{"key":"279_CR43","first-page":"361","volume-title":"Radiation injury to the central nervous system","author":"LM DeAngelis","year":"1991","unstructured":"DeAngelis LM, Shapiro WR (1991) Drug\/radiation interactions and central nervous system injury. In: Gutin PH, Leibel SA, Sheline GE (eds) Radiation injury to the central nervous system. Raven Press, New York, pp 361\u2013382"},{"key":"279_CR44","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/01.WNL.0000109673.75316.D8","volume":"62","author":"DD Correa","year":"2004","unstructured":"Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE (2004) Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62:548\u2013555","journal-title":"Neurology"},{"key":"279_CR45","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/archneur.62.10.1595","volume":"62","author":"AMP Omuro","year":"2005","unstructured":"Omuro AMP, Ben-Porat LS, Panageas KS et al (2005) Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62:1595\u20131600","journal-title":"Arch Neurol"},{"key":"279_CR46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.critrevonc.2007.04.012","volume":"63","author":"AJ Ferreri","year":"2007","unstructured":"Ferreri AJ, Reni M (2007) Primary central nervous system lymphoma. Crit Rev Oncol Hematol 63:257\u2013268","journal-title":"Crit Rev Oncol Hematol"},{"key":"279_CR47","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1200\/JCO.2003.01.135","volume":"21","author":"AJ Ferreri","year":"2003","unstructured":"Ferreri AJ, Abrey LE, Blay JY et al (2003) Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 21:2407\u20132414","journal-title":"J Clin Oncol"},{"key":"279_CR48","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1200\/JCO.1998.16.3.864","volume":"16","author":"JY Blay","year":"1998","unstructured":"Blay JY, Conroy T, Chevreau C et al (1998) High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16:864\u2013871","journal-title":"J Clin Oncol"},{"key":"279_CR49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1008201717089","volume":"8","author":"M Reni","year":"1997","unstructured":"Reni M, Ferreri AJ, Garancini MP, Villa E (1997) Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 8:227\u2013234","journal-title":"Ann Oncol"},{"key":"279_CR50","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","volume":"21","author":"T Batchelor","year":"2003","unstructured":"Batchelor T, Carson K, O\u2019Neill A et al (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96\u201307. J Clin Oncol 21:1044\u20131049","journal-title":"J Clin Oncol"},{"key":"279_CR51","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.pec.2006.11.005","volume":"66","author":"A Mehnert","year":"2007","unstructured":"Mehnert A, Scherwath A, Schimer L et al (2007) The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 66:108\u2013118","journal-title":"Patient Educ Couns"},{"key":"279_CR52","first-page":"1021","volume":"18","author":"S Khalfallah","year":"1996","unstructured":"Khalfallah S, Stamatoullas A, Fruchart C, Proust F, Delangre T, Tilly H (1996) Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transpl 18:1021\u20131023","journal-title":"Bone Marrow Transpl"},{"key":"279_CR53","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.2005.04.8819","volume":"24","author":"T Batchelor","year":"2006","unstructured":"Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24:1281\u20131288","journal-title":"J Clin Oncol"},{"key":"279_CR54","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1200\/JCO.2001.19.3.742","volume":"19","author":"C Soussain","year":"2001","unstructured":"Soussain C, Suzan F, Hoang-Xuan K et al (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19:742\u2013749","journal-title":"J Clin Oncol"},{"key":"279_CR55","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2007.13.5533","volume":"26","author":"C Soussain","year":"2008","unstructured":"Soussain C, Hoang-Xuan K, Taillandier L et al (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 26:2512\u20132518","journal-title":"J Clin Oncol"},{"key":"279_CR56","first-page":"406","volume":"18","author":"C Patte","year":"1990","unstructured":"Patte C, Leverger G, Perel Y et al (1990) Updated results of the LMB86 protocol of the French Pediatric Oncology Society (SFOP) for B-cell non-hodgkin\u2019s lymphoma (B-NHL) with CNS involvement (CNS+) and B-ALL. Med Pediatr Oncol 18:406 (abstr)","journal-title":"Med Pediatr Oncol"},{"key":"279_CR57","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1586\/14737140.7.5.689","volume":"7","author":"E Gerstner","year":"2007","unstructured":"Gerstner E, Batchelor T (2007) Primary CNS lymphoma. Expert Rev Anticanc Ther 7:689\u2013700","journal-title":"Expert Rev Anticanc Ther"},{"key":"279_CR58","first-page":"A2055","volume":"20","author":"LE Abrey","year":"2001","unstructured":"Abrey LE, Moskowitz CH, Mason WP et al (2001) A phase II study of intensive methotrexate and cytarabine followed by high dose BEAM chemotherapy with autologous stem cell transplantation (ASCT) in patients with newly diagnosed primary central nervous system lymphoma (PCNSL). Proc Am Soc Clin Oncol 20:A2055 (abstr 207)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"279_CR59","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2003.05.024","volume":"21","author":"LE Abrey","year":"2003","unstructured":"Abrey LE, Moskowitz CH, Mason WP et al (2003) Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21:4151\u20134156","journal-title":"J Clin Oncol"},{"key":"279_CR60","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1080\/10428190802381238","volume":"49","author":"AJ Ferreri","year":"2008","unstructured":"Ferreri AJ, Crocchiolo R, Assanelli A, Govi S, Reni M (2008) High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk Lymphoma 49:2042\u20132047","journal-title":"Leuk Lymphoma"},{"key":"279_CR61","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/1040-8428(92)90092-5","volume":"13","author":"VJ Wiebe","year":"1992","unstructured":"Wiebe VJ, Smith BR, Degregorio MW, Rappeport JM (1992) Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol 13:241\u2013270","journal-title":"Crit Rev Oncol Hematol"},{"key":"279_CR62","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/0277-5379(86)90315-9","volume":"22","author":"JM Holthus","year":"1986","unstructured":"Holthus JM, Postmus PE, Van Oort WJ et al (1986) Pharmacokinetics of high-dose etoposide (VP16\u2013213). Eur J Cancer Clin Oncol 22:1149\u20131155","journal-title":"Eur J Cancer Clin Oncol"},{"key":"279_CR63","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF00256174","volume":"16","author":"A Gouyette","year":"1986","unstructured":"Gouyette A, Hartmann O, Pico JL (1986) Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 16:184\u2013189","journal-title":"Cancer Chemother Pharmacol"},{"key":"279_CR64","first-page":"944","volume":"12","author":"DHW Ho","year":"1971","unstructured":"Ho DHW, Frei E III (1971) Clinical pharmacology of 1-B-D-ara-binofuranosyl cytosine. Clin Pharmacol 12:944\u2013954","journal-title":"Clin Pharmacol"},{"key":"279_CR65","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/1097-0142(19821001)50:7<1248::AID-CNCR2820500705>3.0.CO;2-5","volume":"50","author":"H Breithaupt","year":"1982","unstructured":"Breithaupt H, Pralle H, Eckhardt T, von Hattingberg M, Schick J, L\u00f6ffler H (1982) Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C). Cancer 50:1248\u20131257","journal-title":"Cancer"},{"key":"279_CR66","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/sj.bmt.1703917","volume":"31","author":"T Cheng","year":"2003","unstructured":"Cheng T, Forsyth P, Chaudhry A et al (2003) High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transpl 31:679\u2013685","journal-title":"Bone Marrow Transpl"},{"key":"279_CR67","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1600-0609.2005.00508.x","volume":"75","author":"M Brevet","year":"2005","unstructured":"Brevet M, Garidi R, Gruson B, Royer B, Vaida I, Damaj G (2005) First-line autologous stem cell transplantation in primary CNS lymphoma. Eur J Haematol 75:288\u2013292","journal-title":"Eur J Haematol"},{"key":"279_CR68","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.bmt.1705452","volume":"38","author":"P Colombat","year":"2006","unstructured":"Colombat P, Lemevel A, Bertrand P et al (2006) High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60\u00a0years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transpl 38:417\u2013420","journal-title":"Bone Marrow Transpl"},{"key":"279_CR69","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","volume":"24","author":"G Illerhaus","year":"2006","unstructured":"Illerhaus G, Marks R, Ihorst G et al (2006) High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24:3865\u20133870","journal-title":"J Clin Oncol"},{"key":"279_CR70","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3324\/haematol.11771","volume":"93","author":"G Illerhaus","year":"2008","unstructured":"Illerhaus G, M\u00fcller F, Feuerhake F, Sch\u00e4fer AO, Ostertag C, Finke J (2008) High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 93:147\u2013148","journal-title":"Haematologica"},{"key":"279_CR71","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/annonc\/mdl458","volume":"18","author":"M Montemurro","year":"2007","unstructured":"Montemurro M, Kiefer T, Sch\u00fcler F et al (2007) Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan\/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe H\u00e4mato-Onkologie OSHO-53 phase II study. Ann Oncol 18:665\u2013671","journal-title":"Ann Oncol"},{"key":"279_CR72","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/10428199909083396","volume":"34","author":"G Varadi","year":"1999","unstructured":"Varadi G, Or R, Kapelushnik J et al (1999) Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Leuk Lymphoma 34:185\u2013190","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-010-0279-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-010-0279-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-010-0279-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T18:15:22Z","timestamp":1635617722000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-010-0279-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,4]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["279"],"URL":"https:\/\/doi.org\/10.1007\/s11060-010-0279-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,4]]}}}